News
3 Long-Term Dividend Buys You Can Get for Under $50
Despite ongoing concerns about overvalued stocks, many value investors sleep well at night. That’s because the key to long-term value investing is total return, which includes a healthy, growing
Unitedhealth Aktie: Wettbewerbsanalyse durchführen
Der Gesundheitsriese UnitedHealth erlebt einen spektakulären Wendepunkt. Die gebeutelte Aktie schnellt im vorbörslichen Handel…
Der Beitrag Unitedhealth Aktie: Wettbewerbsanalyse durchführen
BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2025 sowie Informationen zur Geschäftsentwicklung
- BioNTech treibt Onkologiestrategie voran, u.a. mit zwei bekanntgegeben Transaktionen, und setzt damit den Fokus auf die zwei tumorübergreifenden (Pan-Tumor-)Programme:
Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen
- Studie zur Evaluierung der Wirksamkeit und Sicherheit von Fosmanogepix bei Erwachsenen mit invasiven Schimmelpilzinfektionen
- Studienabschluss im 1. Quartal 2028 erwartet
Allschwil, 29. Juli
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union
- Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu
Unitedhealth Stock: Justice Department Probe Rattles Investors
The healthcare giant UnitedHealth confirmed Thursday it is cooperating with both criminal and civil investigations by the U.S. Justice Department regarding its Medicare Advantage business practices
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Today’s stock market focus is centered on one single sector: technology stocks.
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one
Why Wall Street Is Betting on These 3 Comeback Stocks
The first half of 2025 was a tumultuous time for U.S. securities, to put it mildly. The transition to the second Trump administration brought rapidly shifting domestic and international policies
MSD Stock: Pharma Giant's $10 Billion Verona Acquisition
Merck & Co. is poised to make its largest acquisition in two years, agreeing to purchase British biotech firm Verona Pharma for approximately $10 billion. The pharmaceutical giant will pay $107 per
Do They Know Something? Insiders & Congress Buy UnitedHealth
UnitedHealth Group (NYSE: UNH) has spent a significant amount of time in the sick bay for the first half of 2025, but it’s showing signs of recovery.
Let’s get the bad news out of the way
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
In a market where mega-cap growth and tech stocks continue to dominate headlines and stretch valuations, income-oriented investors may feel sidelined. But for those with a long-term perspective
UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
UnitedHealth Group (NYSE: UNH) is a dominant force within the healthcare sector, a critical industry that should be included in a diversified long-term
Merck Stock: Dual Challenges for Pharma Giant
Merck & Co., known as MSD outside North America, faces significant developments in both its pharmaceutical and animal health divisions that could impact investor sentiment. The company recently
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an
- Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der
3 Oversold Stocks Flashing Bullish Reversal Signals
When it comes to short-term trading signals, few indicators are as closely tracked as the Relative Strength Index (RSI). A stock’s RSI measures the speed and magnitude of its recent price
Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen weitere Meilensteinzahlung an Basilea aus
Allschwil, 05. Juni 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren
Johnson & Johnson Stock: Cancer Breakthroughs Spark Mixed Market Reactions
Johnson & Johnson is generating significant attention in both medical and financial circles following impressive study results for its multiple myelom treatments. The pharmaceutical giant's cancer
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking
3 Trades Members of Congress Are Making Right Now
Whether or not members of Congress should be allowed to buy or sell stocks is another topic. Retail investors should keep their eyes on the ball. That means, if investors can’t beat them, they may
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the one-sided machine it used to be a few decades ago. Thanks to the flow of
Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal
Pharmaceutical giant Pfizer is making significant strategic moves in oncology, investing up to $6 billion in a licensing deal with Chinese biotech firm 3SBio. The agreement centers on SSGJ-707, a
UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
Despite the healthcare sector's reputation for stability, UnitedHealth Group (NYSE: UNH) has recently faced significant market turbulence.
By mid-May
UnitedHealth Stock: Justice Department Probe Triggers Freefall
UnitedHealth Group finds itself in severe turmoil as shares plummeted nearly 11% to $245.90 following news of a U.S. Justice Department criminal investigation into potential Medicare fraud. The
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie Informationen zur Geschäftsentwicklung
- Weiterentwicklung der Onkologie-Pipeline vorangetrieben mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme: Immunmodulator-Kandidat BNT327, ein gegen PD-L1 und VEGF-A1
3 Stocks to Buy Now for Tariff Immunity
There’s a new commodity in the financial markets today, and that’s any stock (or business, for that matter) that carries a certain level of immunity to the recent trade tariffs rolled out by